Back to search results

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Gastric Cancer · Esophageal Cancer · Stomach Cancer · Esophagus Cancer · Gastroesophageal Junction Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Washington University School of Medicine, St Louis, Missouri, United States

    Contact: Study coordinator (Patrick Grierson, M.D., Ph.D.) · grierson@wustl.edu · 314-747-7689
    Contact: Principal Investigator (Patrick Grierson, M.D., Ph.D.)
    Olivia Aranha, M.D., Ph.D. (Sub-investigator)
    Matthew Ciorba, M.D. (Sub-investigator)
    Kian-Huat Lim, M.D., Ph.D. (Sub-investigator)
    Michael Iglesia, M.D., Ph.D. (Sub-investigator)
    Katrina Pedersen, M.D. (Sub-investigator)
    Rama Suresh, M.D. (Sub-investigator)
    Benjamin Tan, M.D. (Sub-investigator)
    Nikolaos Trikalinos, M.D. (Sub-investigator)
    David DeNardo, Ph.D. (Sub-investigator)
    Feng Gao, Ph.D. (Sub-investigator)
Study leads

  • Patrick Grierson, M.D., Ph.D.

    Principal Investigator

    Washington University School of Medicine

View source on ClinicalTrials.gov(opens in a new tab)